Sun Pharma, Aurobindo recall products in US over defaulting norms

Published On 2022-02-28 07:48 GMT   |   Update On 2023-10-18 09:41 GMT

New Delhi: Leading homegrown drug makers Aurobindo Pharma and Sun Pharmaceutical Industries are recalling different products in the US market due to deviation from standard manufacturing norms. 

According to the latest enforcement report issued by the US Food and Drug Administration (USFDA), the US-based arm of Aurobindo Pharma is recalling 1,15,776 bottles of Moxifloxacin Ophthalmic Solution, an antibiotic used in the treatment of bacterial infections.

Advertisement

According to the USFDA, the Princeton-based Aurobindo Pharma USA Inc is recalling the affected lot due to ''failed impurities/degradation specifications''.

The company initiated the nationwide Class II recall on January 14 this year.

Read Also - Unichem, Aurobindo Pharma recall Topiramate, Carvedilol respectively in US

The USFDA said the US-based arm of Sun Pharma is recalling 59,232 bottles of Chlorthalidone tablets, used for reducing excess fluid levels in the body.

Advertisement

As per the US health regulator, the New Jersey-based Sun Pharma Inc is recalling the affected lot due to ''foreign matter identified as stainless steel microscopic wear particles mixed with punch lubricant oil and silicone particles from the dust cup''.

Read Also - Aurobindo Pharma launches COVID-19 drug Molnupiravir

The company initiated the Class II voluntary recall on February 7, 2022. 

As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

According to industry estimates, the US generic drug market was estimated to be around USD 115.2 billion in 2019.

Read Also - Aurobindo Pharma in trouble for manufacturing lapses at API plant

Aurobindo Pharma Limited is a pharmaceutical company that manufactures generic pharmaceutical ingredients. The company works in six major therapeutic/product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. Aurobindo Pharma's marketing partners include AstraZeneca and Pfizer. 

Tags:    
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News